Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-11-26

Clinical Trial Update: Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding [Phase 3]

View source ↗

Summary

A Phase 3 trial of recombinant coagulation factor VIIa in patients with severe bleeding was terminated; results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Trauma | Phase 3 | Status: TERMINATED | Results posted: 2009-11-26